News & Media

282025-03

Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

292026-07

First Patient Randomized in Mabgeek Biotech’s Global Multicenter Phase III Trial of Comekibart (MG-K10) for Atopic Dermatitis

Recently, comekibart, a long-acting humanized monoclonal antibody targeting IL-4Rα independently dev
152026-07

Comekibart Shows Early Promise for Once-Every-Eight-Weeks Dosing

Recently, Mabgeek Biotech completed a Phase II clinical study evaluating comekibart (MG-K10), admini
092026-06

Mo Xian., et al. 2026, Clinical &Experimental Allergy

Clin Experimental Allergy - 2026 - Xian - Phase Ib II Study of Preliminary Efficacy Safety and Phar

Technological innovation

Efficient integration; Establish an efficient antigen-antibody expression and purification platform.

All team members come from well-known domestic pharmaceutical companies, and the team has over three years of cooperation experience.

The company has a 500-square-meter laboratory and four cell culture rooms.

Independent R&D and clinical development of innovative antibodies have resulted in the first domestic market launch and the first global submission.

About Us

About
R&D
- Areas
- Pipeline
- Platforms
Publications
- MG-K10
- MG-ZG122
Careers
- Culture
- Join Us

Contact Us

ADD:No.5, Building 34, Lane 122, Chunxiao Road, Zhangjiang Town, Pudong New Area, Shanghai
TEL: +86-21-51371305
EMAlL:info@mabgeek.com

All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com

湘ICP备2024096314号公安部备案：31011502015815